2023 Targeted Therapies of Lung Cancer Meeting

CONTACT US
Facebook-f Twitter Linkedin Youtube

Conquering Thoracic Cancers Worldwide

Menu

Confirmed Supporters & Exhibitors

Twitter feed is not available at the moment.

The IASLC 2023 Targeted Therapies of Lung Cancer Meeting (TTLC 2023) would like to thank the following companies for their support:

DIAMOND LEVEL

AstraZeneca

Genentech

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Genentech

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions

GOLD LEVEL

Amgen

BMS

Regeneron

Amgen

Amgen is a worldwide leader in biotechnology. For more than forty years, we’ve pursued some of the greatest challenges facing human health, marrying science and technological innovation with the passion of our staff, to serve patients and find new solutions that meet the growing demand for better quality healthcare for more people worldwide

BMS

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Regeneron

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

SILVER LEVEL

Abbvie

Janssen Pharmaceutical Companies of Johnson & Johnson

Jazz Pharmaceuticals Inc.

Lilly

Sanofi

Abbvie

At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology

Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism, & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com.

Jazz Pharmaceuticals Inc.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.

Lilly

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

Sanofi

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine for patients. Our approach is shaped by our experience developing specialized treatments and forging relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

BRONZE LEVEL

BeiGene

Janssen Oncology, RYBREVANT®

Mirati Therapeutics, Inc.

Takeda Oncology

BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.

Janssen Oncology, RYBREVANT®

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism, & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com.

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer.

Takeda Oncology

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our leadership in oncology extends more than 25 years and includes a range of therapies that have helped to transform the treatment landscape for previously underserved patient populations, in some cases shifting paradigms and becoming standard of care. We are building on our portfolio of approved medicines for hematologic cancers and solid tumors and advancing a cutting-edge pipeline focused on the power of innate immunity. We aim to introduce new classes of immunotherapies that can lead to deep, durable responses so that more patients can benefit from – and have access to – innovative medicines.

EXHIBITORS

Merck

Novocure

Merck

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Opening Reception Supported by

Contact Us

For information regarding promotion & advertising, symposia and exhibit opportunities, please contact: 

International Association for the Study of Lung Cancer (IASLC)
[email protected]